Abstract 461P
Background
Meta-analyses and cohort studies have shown blood trace mineral concentration may be associated with incidence risk of lung cancer. However, there is no comprehensive study to investigate causal relationship between blood trace mineral and lung cancer. The purpose of this study is to inspect the causal effect of blood trace mineral concentration on lung cancer with Mendelian randomization (MR) method.
Methods
With a two‐sample MR approach, we analyzed the summary data of zinc, selenium, copper from the Queensland Institute of Medical Research(QIMR, 2603 individuals) and The Avon Longitudinal Study of Parents and Children (ALSPAC, 10115 individuals), data of calcium from discovery cohorts(39400 individuals) and replication cohorts(21875 individuals), data of iron from Genetics of Iron Status Consortium(23986 individuals), data of lung cancer patients from Consortium and International Lung Cancer Consortium (ILCCO, 11 348 lung cancer cases and 15 861 controls) to assess the possible causal relationship of blood trace mineral concentration on the risk of lung cancer.
Results
Our results indicated that genetically predicted higher blood copper level has a positive association with lung cancer, each per-unit increase in copper is associated with a 14% increase in the risk of lung cancer (odds ratio [OR]: 1.14, 95% CI = 1.01‐1.29; P = 0.04). Additionally, blood calcium, zinc, selenium, iron were not causal factors for lung cancer.
Conclusions
Genetically higher blood copper is positively associated with risk of lung cancer, and more work is needed to examine the potential mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503); Science and Technology Program of Guangdong (Grant No. 2017B020227001, 2016A020215084); Science and Technology Program of Guangzhou (Grant No. 201607020031, 201400000001-2); Chinese National Natural Science Foundation project (Grant No. 81772476, 81572659,81602011); Pearl River Nova Program of Guangzhou (Grant No. 201610010048); National Natural Science Funds for Young Scholars of China (Grant No. 81502355).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract